Medical uses and spectrum of activity
- Treatment of acne
- Treatment of cholera
- Treatment of brucellosis
- Treatment of plague
- Treatment of malaria
- Broad spectrum of antibiotic action
- Bacteriostatic activity against aerobic and anaerobic bacteria
- Exceptions: Pseudomonas aeruginosa and Proteus spp.
- Acquired resistance in many pathogenic organisms
- Useful in managing infections by certain intracellular bacterial pathogens
Anti-eukaryote use
- Activity against certain eukaryotic parasites
- Effective against dysentery caused by an amoeba
- Effective against malaria caused by a plasmodium
- Effective against balantidiasis caused by a ciliate
Use as a biomarker
- Tetracycline hydrochloride used as a marker of bone growth in humans
- Incorporated into mineralizing bone and detected by fluorescence
- Double tetracycline labeling used to measure bone growth
- Used as a biomarker in wildlife to detect consumption of medicine-containing baits
Side effects
- Discoloration of permanent teeth, especially in children
- Inactivation by calcium, aluminum, iron, and zinc ions
- Skin photosensitivity
- Drug-induced lupus and hepatitis
- Breathing complications and anaphylactic shock in some individuals
History and society
- Tetracyclines discovered by Benjamin Minge Duggar in 1948
- Tetracycline antibiotic, chlortetracycline (Aureomycin), discovered in 1945
- Structure of Aureomycin elucidated in 1952 and published in 1954
- Tetracycline received FDA approval in 1954
- Tetracycline can be identified in bones using ultraviolet light
- Nubian mummies from 350-550 A.D. showed patterns of fluorescence similar to modern tetracycline-labeled bone
- Price of tetracycline in the USA rose significantly from 2013 to 2015
- Tetracycline marketed under various brand names
- Tetracycline used in genetic engineering and research
Tetracycline, sold under various brand names, is an oral antibiotic in the tetracyclines family of medications, used to treat a number of infections, including acne, cholera, brucellosis, plague, malaria, and syphilis.
Clinical data | |
---|---|
Pronunciation | /ˌtɛtrəˈsaɪkliːn/ |
Other names | TE/TET/TC/TCY |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682098 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 80% |
Metabolism | Not metabolised |
Elimination half-life | 8–11 hours, 57–108 hours (kidney impairment) |
Excretion | Urine (>60%), feces |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.438 |
Chemical and physical data | |
Formula | C22H24N2O8 |
Molar mass | 444.440 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Common side effects include vomiting, diarrhea, rash, and loss of appetite. Other side effects include poor tooth development if used by children less than eight years of age, kidney problems, and sunburning easily. Use during pregnancy may harm the baby. It works by inhibiting protein synthesis in bacteria.
Tetracycline was patented in 1953 and was approved for prescription use in 1954. It is on the World Health Organization's List of Essential Medicines. Tetracycline is available as a generic medication. Tetracycline was originally made from bacteria of the genus Streptomyces.
From tetracyclic + -ine.
tetracycline (countable and uncountable, plural tetracyclines) (abbreviated tet)